171 related articles for article (PubMed ID: 36089920)
1. Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS; Li G; Tolba K; Bourla AB; Schulze K; Gadgil R; Fine A; Lofgren KT; Graf RP; Oxnard GR; Daniel D
JTO Clin Res Rep; 2022 Sep; 3(9):100386. PubMed ID: 36089920
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
Oncol Ther; 2024 Mar; ():. PubMed ID: 38502426
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
4. Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
Mack PC; Keller-Evans RB; Li G; Lofgren KT; Schrock AB; Trabucco SE; Allen JM; Tolba K; Oxnard GR; Huang RSP
Oncologist; 2024 Feb; ():. PubMed ID: 38401173
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
8. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
Li G; Pavlick D; Chung JH; Bauer T; Tan BA; Peguero J; Ward P; Kallab A; Bufill J; Hoffman A; Sadiq A; Edenfield J; He J; Cooke M; Hughes J; Forcier B; Nahas M; Stephens P; Ali SM; Schrock AB; Ross JS; Miller VA; Gregg JP
J Gastrointest Oncol; 2019 Oct; 10(5):831-840. PubMed ID: 31602320
[TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
12. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
14. Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Pritchett MA; Camidge DR; Patel M; Khatri J; Boniol S; Friedman EK; Khomani A; Dalia S; Baker-Neblett K; Plagnol V; Howarth KD; Jones GR; Rosenfeld N; Morris CD; Govindan R
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914040
[TBL] [Abstract][Full Text] [Related]
15. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Antonarakis ES; Tierno M; Fisher V; Tukachinsky H; Alexander S; Hamdani O; Hiemenz MC; Huang RSP; Oxnard GR; Graf RP
Prostate; 2022 May; 82(7):867-875. PubMed ID: 35286728
[TBL] [Abstract][Full Text] [Related]
17. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
18. Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.
Singh AP; Shum E; Rajdev L; Cheng H; Goel S; Perez-Soler R; Halmos B
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32375398
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.
Lee JK; Madison R; Classon A; Gjoerup O; Rosenzweig M; Frampton GM; Alexander BM; Oxnard GR; Venstrom JM; Awad MM; Schrock AB
JCO Precis Oncol; 2021; 5():. PubMed ID: 34476332
[TBL] [Abstract][Full Text] [Related]
20. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Tomlins SA; Hovelson DH; Suga JM; Anderson DM; Koh HA; Dees EC; McNulty B; Burkard ME; Guarino M; Khatri J; Safa MM; Matrana MR; Yang ES; Menter AR; Parsons BM; Slim JN; Thompson MA; Hwang L; Edenfield WJ; Nair S; Onitilo A; Siegel R; Miller A; Wassenaar T; Irvin WJ; Schulz W; Padmanabhan A; Harish V; Gonzalez A; Mansoor AH; Kellum A; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]